Dynamics of eligibility criteria for central nervous system metastases in non-small cell lung cancer randomized clinical trials over time: A systematic review-Reference-Cited by-同舟云学术

Dynamics of eligibility criteria for central nervous system metastases in non-small cell lung cancer randomized clinical trials over time: A systematic review

Published:2021-10 Issue: Volume:166 Page:103460
ISSN:1040-8428
Container-title:Critical Reviews in Oncology/Hematology
language:en
Short-container-title:Critical Reviews in Oncology/Hematology

Author:

Schoenmaekers Janna Josephus Anna Oda,Dursun Safiye,Biesmans Charlotte,De Ruysscher Dirk Karel Maria,Broen Martinus Petrus Gertrudis^ORCID,Remon Jordi^ORCID,Dingemans Anne-Marie Clasina,Hendriks Lizza Elisabeth Lucia^ORCID

Publisher

Elsevier BV

Subject

Oncology,Hematology

Reference52 articles.

1. Five-year outcomes with pembroluzimab versus chemotherapy for metastastic non-small-cell lung cancer with PD-L1 tumor proportion score ≥ 50;Reck;J. Clin. Oncol.,2021

2. Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer;Antonia;N. Engl. J. Med.,2017

3. Updated efficacy and safety data and impact of the EML4-ALK fusion variant on the efficacy of Alectinib in untreated ALK-positive advanced non-small cell lung cancer in the global phase III ALEX study;Camidge;J. Thorac. Oncol.,2019

4. Clinical trial design for systemic agents in patients with brain metastases from solid tumours: a guideline by the Response Assessment in Neuro-Oncology Brain Metastases working group;Camidge;Lancet Oncol.,2018

5. Brigatinib versus crizotinib in ALK-positive non-small-cell lung cancer;Camidge;N. Engl. J. Med.,2018

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Central nervous system metastases in advanced non-small cell lung cancer: A review of the therapeutic landscape;Cancer Treatment Reviews;2024-11

2. Resection of the Primary Tumor and Survival in Patients with Single-Site Synchronous Oligometastatic Non–Small Cell Lung Cancer: Propensity-Matched Analysis of the National Cancer Database;Journal of the American College of Surgeons;2024-02-09

3. Impact of first-line immunotherapy on survival and intracranial outcomes in a cohort of non-small cell lung cancer patients with brain metastases at diagnosis;Lung Cancer;2023-10

4. The Current Landscape of Immune Checkpoint Inhibitor Immunotherapy for Primary and Metastatic Brain Tumors;Antibodies;2023-04-04

5. Emerging Systemic Treatment Perspectives on Brain Metastases: Moving Toward a Better Outlook for Patients;American Society of Clinical Oncology Educational Book;2022-07